FORT COLLINS, Colo., May 19, 2021 /PRNewswire/ — GT Molecular, a company providing multiplexed, ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels for clinical labs, has started shipping its sensitive PCR tests to monitor the coronavirus variant, B.1.617. The virus was first spotted in India and upgraded to a global variant of concern by the WHO. It is sometimes referred to as the double mutant because it contains two mutations of concern and has been reported to be highly contagious and potentially capable of evading the immune system.
Two offerings are available:
These new offerings add to GT Molecular’s growing molecular assay catalog that includes SARS-CoV-2 multi-variant tests, cancer panels, multiplexed pathogen panels for clinical labs and quantitative standards.
About GT Molecular
GT Molecular is a leader in providing highly customizable, ultrasensitive digital PCR and qPCR tests. GTM’s molecular app technology is an easy-to-use, end-to-end solution for rapid deployment and provides reliable and consistent measurements while detecting as little as 1-3 molecules of target nucleic acid.
ORDER & INFORMATION: info@gtmolecular.com, 970-498-1698
View original content:http://www.prnewswire.com/news-releases/gt-molecular-launches-highly-sensitive-multiplexed-pcr-tests-for-the-indian-coronavirus-variant-301295109.html
SOURCE GT Molecular
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical…
/NOT FOR DISSEMINATION IN THE UNITED STATES/ MONTRÉAL, Nov. 25, 2024 /CNW/ - METRO INC. ("Metro")…
DALLAS, Nov. 25, 2024 /PRNewswire/ -- Loopback Analytics has been honored by the Dallas Business Journal as…
Mercy the only health care organization represented in policy discussion ST. LOUIS, Nov. 25, 2024…
After a successful 6-week pilot program, Nabla's ambient AI assistant is rolling out to Catalight's…
NEW YORK, Nov. 25, 2024 /PRNewswire/ -- The global electronic health records market size is estimated to…